Zentalis Pharmaceuticals Inc (ZNTL)
$4.47
+0.11
(+2.52%)▲
Performance
- $4.30$4.62$4.47
3.8%
Downside
Day's Volatility :6.93%
Upside
3.25%
- $3.27$29.03$4.47
26.85%
Downside
52 Weeks Volatility :88.74%
Upside
84.6%
Returns
| Period | Zentalis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -60.58% | 6.5% | 0.0% |
6 Months | -65.62% | 7.1% | 0.0% |
1 Year | -83.18% | 9.8% | 0.0% |
3 Years | -91.56% | 14.2% | -20.2% |
Highlights
Market Capitalization | 306.1M |
Book Value | $6.46 |
Earnings Per Share (EPS) | -3.26 |
Wall Street Target Price | 10.7 |
Profit Margin | 0.0% |
Operating Margin TTM | -61.06% |
Return On Assets TTM | -24.93% |
Return On Equity TTM | -51.87% |
Revenue TTM | 40.6M |
Revenue Per Share TTM | 0.59 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -207.4M |
Diluted Eps TTM | -3.26 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.68 |
EPS Estimate Next Year | -3.62 |
EPS Estimate Current Quarter | -0.77 |
EPS Estimate Next Quarter | -0.94 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 139.37%
Technicals Summary
Sell
Neutral
Buy
Zentalis Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Zentalis Pharmaceuticals Inc | 4.81% | -65.62% | -83.18% | -91.56% | -81.21% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | NA | NA | NA | -2.68 | -0.52 | -0.25 | NA | 6.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | Buy | $306.1M | -81.21% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Zentalis Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 144.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 278.1%
Institutional Holdings
Matrix Capital Management Company, LLC
19.66%Eventide Asset Management, LLC
16.30%FMR Inc
14.99%BlackRock Inc
6.54%Vanguard Group Inc
6.19%State Street Corporation
5.33%
Company Information
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Organization | Zentalis Pharmaceuticals Inc |
Employees | 124 |
CEO | Dr. Kimberly Lynn Blackwell M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$4.47
+2.52%
Keyarch Acquisition Corp
$4.47
+2.52%
Connexa Sports Technologies Inc
$4.47
+2.52%
Us Value Etf
$4.47
+2.52%
First Wave Biopharma Inc
$4.47
+2.52%
Global X Msci Next Emerging
$4.47
+2.52%
Fat Projects Acquisition Corp
$4.47
+2.52%
Capital Link Global Fintech
$4.47
+2.52%
Applied Uv Inc
$4.47
+2.52%